Background A quantitative measurement of serum proteome biomarkers that would
associate with disease progression endpoints can provide risk stratification for persons with …

Serum neurofilament light chain (sNfL) levels have been proposed as a biomarker of the
clinical activity, disability progression, and response to treatment of people with multiple …

In 2023, three prominent themes have dominated multiple sclerosis research:(1) the view of
the disease as a continuum, whereby inflammation and neurodegeneration coexist from …

Conclusion While we have made significant advances in monitoring the disease, we are still
desperately searching for this one blood marker, which will reassure us that we are treating …

Discovery of serum protein biomarkers for Multiple Sclerosis risk and severity could shed
light on pathophysiological mechanisms, suggest new drug targets, enhance the speed of …

Background: Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are
biomarkers of neuronal injury measurable in cerebrospinal fluid (CSF) and blood. Despite …

B cell depletion is becoming a preferred long-term treatment even in early multiple sclerosis,
but concerns about the risks of impaired immune competence persist. In their observational …

Bei der Multiplen Sklerose ist die frühe Diagnose und Prognoseabschätzung eine wichtige
Voraussetzung für eine möglichst frühe und gezielte effektive Therapie. Auch wenn kein …

Serum neurofilament light chain (sNfL) levels have been proposed as a biomarker of the
clinical activity, disability progression, and response to treatment of people with multiple …

Over the past decade, knowledge of the pathophysiology and immunology of multiple
sclerosis (MS) and depression, and the complex links to vitamin D (VitD) balance, has …